Table 2 Comparison of the Sox9-Pten with Alb-Pten mice.

From: Transformation of SOX9+ cells by Pten deletion synergizes with steatotic liver injury to drive development of hepatocellular and cholangiocarcinoma

 

Sox9-Cre

Albumin-Cre

8.5–9.5 M

Controla (n = 7)b

Sox9-Pten (n = 7)b

Control (n = 16)b

Alb-Pten (n = 30)b

Fatty liverc

0/6

Periductal area

NO

Entire liver

VMCd

0/6

4/7 (57.1%)

0/16 (0%)

30/30 (100%)

Tumorsd

0/6

0/7 (0%)e

0/16 (0%)

14/30 (46.7%)

11-13 M

Control (n = 13)2

Sox9-Pten (n = 22)2

Control (n = 126)2

Alb-Pten (n = 48)2

Fatty liverc

NO

Periductal area

NO

Entire liver

VMCd

0/13 (0%)

18/22 (81.8%)

0/126 (0%)

48/48 (100%)

Tumorsd

0/13 (0%)

14/22 (63.6%)

0/126 (0%)

48/48 (100%)

  1. VMC von Meyenburg complex.
  2. aControl mice are: Pten loxP/loxP; Cre- mice with no treatment; Pten + / + ; Sox9-CreERT mice treated with either corn oil or tamoxifen; or PtenloxP/loxP; Sox9-CreERT mice treated with coil oil.
  3. bThe number of mice in each cohort at different ages.
  4. cThe location where lipids accumulate in the liver.
  5. dOut of the total number of mice in each cohort (the number shown after slash), the number of mice developing these phenotypes is shown before slash. The percentage of mice developing these phenotypes in each cohort is shown accordingly in prentices.
  6. eStatistically significantly different (P < 0.05) from that of Alb-Pten group using Fischer’s exact test.
Back to article page